Gilead Sciences Inc (GILD)

86.55
NASDAQ : Health Care
Prev Close 87.24
Day Low/High 86.32 / 87.44
52 Wk Low/High 77.92 / 120.37
Avg Volume 9.48M
Exchange NASDAQ
Shares Outstanding 1.33B
Market Cap 116.19B
EPS 12.40
P/E Ratio 7.27
Div & Yield 1.88 (2.20%)

Latest News

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?

Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report

Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report

Gilead Sciences (GILD) is scheduled to report earnings on Monday, July 25 after the market close.

European CHMP Adopts Positive Opinion On Gilead's Type II Variation Application For Truvada® For Reducing The Risk Of Sexually Acquired HIV

European CHMP Adopts Positive Opinion On Gilead's Type II Variation Application For Truvada® For Reducing The Risk Of Sexually Acquired HIV

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the...

Gilead's Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective In Two Phase 3b Studies

Gilead's Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective In Two Phase 3b Studies

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3b switch studies evaluating Odefsey ® (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met...

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Gilead Sciences To Release Second Quarter 2016 Financial Results On Monday, July 25, 2016

Gilead Sciences To Release Second Quarter 2016 Financial Results On Monday, July 25, 2016

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes.

Don’t Give Up On Gilead Sciences

Don’t Give Up On Gilead Sciences

The biotech juggernaut still has a lot going for it, especially at these levels.

Things Are too Giddy for My Taste

But without negative divergences of consequence it’s hard to be bearish,

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Jim Cramer's 'Mad Money' Recap: Stock Prices Just Getting Started

Jim Cramer's 'Mad Money' Recap: Stock Prices Just Getting Started

Listen to what the companies are actually telling you. Then assess what that might mean for the future, Cramer says.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

The GOP's Tax Plan Is Great for Corporate America

The GOP's Tax Plan Is Great for Corporate America

The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

An earlier rally lasted through the afternoon, pushing the S&P 500 and Dow Jones Industrial Average to close at fresh records.

Gilead (GILD) Stock Advancing on Credit Suisse Note

Gilead (GILD) Stock Advancing on Credit Suisse Note

Shares of Gilead (GILD) are up after Credit Suisse released a bullish note on the company.

Gilead's Major Trend Is Still Down

Gilead's Major Trend Is Still Down

Each bounce in the stock has been followed by a move to lower lows.

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Jim Cramer's 'Mad Money' Recap: I'll Tell You Why This Market Is Jumping

Jim Cramer's 'Mad Money' Recap: I'll Tell You Why This Market Is Jumping

Cramer says there are several reasons why the market has risen since the Brexit vote.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

Biogen: Quality at a Discount

Biogen: Quality at a Discount

Biotechs now offer some great valuations, and BIIB is prime example.

Gilead (GILD) Stock Rising on European Regulatory Approval

Gilead (GILD) Stock Rising on European Regulatory Approval

Gilead (GILD) announced today that it has won approval for its hepatitis-C medication from the European Commission.

European Commission Grants Marketing Authorization For Gilead's Epclusa® (Sofosbuvir/Velpatasvir) For The Treatment Of All Genotypes Of Chronic Hepatitis C

European Commission Grants Marketing Authorization For Gilead's Epclusa® (Sofosbuvir/Velpatasvir) For The Treatment Of All Genotypes Of Chronic Hepatitis C

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission has granted marketing authorization for Epclusa ® (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet regimen...

Gilead (GILD) Stock Climbs as Leerink Raises Estimates

Gilead (GILD) Stock Climbs as Leerink Raises Estimates

As second quarter results are typically the strongest for biotech companies, analysts at Leerink are raising their estimates for Gilead (GILD).

Are Gilead, Sirius, Netflix Buys? Check This Measure

Are Gilead, Sirius, Netflix Buys? Check This Measure

It's a fool's game to focus on whether or not a company's quarterly earnings beat Wall Street's expectations, according to one analyst. Here's what you should do instead.

Getting Inside the Accounting at Gilead, Sirius and Netflix

Getting Inside the Accounting at Gilead, Sirius and Netflix

Focusing on whether or not a company's quarterly earnings beats Wall Street's analyst consensus is a foolish game.

The Week's Events Were a Reset, and Bonds Are the Key to the Markets: Best of Kass

The Week's Events Were a Reset, and Bonds Are the Key to the Markets: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us that bankers are feckless and that a blow-off could come with a major cycle end.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

5 Top Stocks Investment Guru Joel Greenblatt Would Love

5 Top Stocks Investment Guru Joel Greenblatt Would Love

His magic formula is no magic bullet, but these companies offer attractive valuations and high returns on capital.